Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Price:
8.2
HKD
2.5%
Market Closed
Market Cap:
HK$6.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
|
CN |
|
Craneware PLC
LSE:CRW
|
UK |
|
Thai Beverage PCL
OTC:TBVPF
|
TH |
|
Visaka Industries Ltd
NSE:VISAKAIND
|
IN |
|
Chaoda Modern Agriculture Holdings Ltd
HKEX:682
|
HK |
|
EFG International AG
OTC:EFGIF
|
CH |
|
S
|
Skyline Investment SA
WSE:SKL
|
PL |
|
Track & Field Co SA
BOVESPA:TFCO4
|
BR |
|
Trinseo PLC
NYSE:TSE
|
US |
|
P
|
Perrigo Company PLC
SWB:PIG
|
IE |
|
Lumax AutoTechnologies Ltd
NSE:LUMAXTECH
|
IN |
|
P
|
Philippine Realty and Holdings Corp
XPHS:RLT
|
PH |
|
Hatsun Agro Product Ltd
NSE:HATSUN
|
IN |
|
Benchmark Electronics Inc
NYSE:BHE
|
US |
|
Nisun International Enterprise Development Group Co Ltd
NASDAQ:NISN
|
CN |
|
Bravida Holding AB
STO:BRAV
|
SE |
Income Statement
Earnings Waterfall
Jacobio Pharmaceuticals Group Co Ltd
Jacobio Pharmaceuticals Group Co Ltd
Income Statement
Jacobio Pharmaceuticals Group Co Ltd
Jacobio Pharmaceuticals Group Co Ltd
Currency: CNY
| Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||
| Interest Expense |
1
|
1
|
1
|
0
|
2
|
6
|
8
|
8
|
7
|
5
|
0
|
|
| Revenue |
486
N/A
|
544
+12%
|
153
-72%
|
150
-2%
|
96
-36%
|
81
-15%
|
64
-22%
|
23
-63%
|
156
+572%
|
201
+29%
|
54
-73%
|
|
| Gross Profit | ||||||||||||
| Cost of Revenue |
(44)
|
(97)
|
(140)
|
(133)
|
(83)
|
(75)
|
(60)
|
(22)
|
0
|
0
|
(1)
|
|
| Gross Profit |
442
N/A
|
447
+1%
|
13
-97%
|
17
+33%
|
13
-26%
|
6
-51%
|
3
-48%
|
1
-75%
|
156
+19 339%
|
201
+29%
|
53
-74%
|
|
| Operating Income | ||||||||||||
| Operating Expenses |
(233)
|
(289)
|
(314)
|
(375)
|
(486)
|
(510)
|
(411)
|
(381)
|
(360)
|
(275)
|
(233)
|
|
| Selling, General & Administrative |
(53)
|
(59)
|
(44)
|
(49)
|
(42)
|
(43)
|
(45)
|
(44)
|
(38)
|
(38)
|
(30)
|
|
| Research & Development |
(181)
|
(231)
|
(277)
|
(336)
|
(441)
|
(468)
|
(364)
|
(350)
|
(308)
|
(237)
|
(170)
|
|
| Depreciation & Amortization |
(5)
|
(7)
|
(5)
|
0
|
(6)
|
0
|
(10)
|
0
|
(26)
|
(11)
|
(23)
|
|
| Other Operating Expenses |
7
|
7
|
11
|
9
|
2
|
1
|
8
|
13
|
13
|
12
|
(10)
|
|
| Operating Income |
209
N/A
|
157
-25%
|
(302)
N/A
|
(358)
-19%
|
(474)
-32%
|
(504)
-6%
|
(408)
+19%
|
(380)
+7%
|
(204)
+46%
|
(73)
+64%
|
(180)
-146%
|
|
| Pre-Tax Income | ||||||||||||
| Interest Income Expense |
(28)
|
(35)
|
0
|
66
|
102
|
93
|
49
|
20
|
46
|
34
|
15
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
4
|
(0)
|
19
|
|
| Total Other Income |
(1 695)
|
(962)
|
0
|
0
|
0
|
0
|
(0)
|
(2)
|
(2)
|
(6)
|
0
|
|
| Pre-Tax Income |
(1 514)
N/A
|
(839)
+45%
|
(301)
+64%
|
(292)
+3%
|
(372)
-27%
|
(410)
-10%
|
(359)
+12%
|
(362)
-1%
|
(156)
+57%
|
(46)
+71%
|
(146)
-220%
|
|
| Net Income | ||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(1 514)
|
(839)
|
(301)
|
(292)
|
(372)
|
(410)
|
(359)
|
(362)
|
(156)
|
(46)
|
(146)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(1 514)
N/A
|
(839)
+45%
|
(301)
+64%
|
(292)
+3%
|
(372)
-27%
|
(410)
-10%
|
(359)
+12%
|
(362)
-1%
|
(156)
+57%
|
(46)
+71%
|
(146)
-220%
|
|
| EPS (Diluted) |
-1.99
N/A
|
-1.11
+44%
|
-0.4
+64%
|
-0.39
+3%
|
-0.49
-26%
|
-0.54
-10%
|
-0.46
+15%
|
-0.47
-2%
|
-0.2
+57%
|
-0.06
+70%
|
-0.19
-217%
|
|
Switch to:
Switch to:
See Also
Discover More
